(Q39845890)

English

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen (English)

1 reference

Europe PubMed Central

15 September 2017

vector-borne disease

0 references

1 reference

based on heuristic

inferred from title

author name string

Sumiti Jain

1

1 reference

Europe PubMed Central

15 September 2017

Amy J Patrick

2

1 reference

Europe PubMed Central

15 September 2017

Kenneth L Rosenthal

3

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

17 August 2010

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

28

1 reference

Europe PubMed Central

15 September 2017

43

1 reference

Europe PubMed Central

15 September 2017

7070-7080

1 reference

Europe PubMed Central

15 September 2017

Targeting early infection to prevent HIV-1 mucosal transmission.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

HPV vaccines: preclinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Virus-like particle and DNA-based candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

A high-efficiency Cre/loxP-based system for construction of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Heterologous prime-boost vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Characterization of a trimeric MPER containing HIV-1 gp41 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Prediction of linear B-cell epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Ab and T cell epitopes of influenza A virus, knowledge and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

HIV-1 derived peptides fused to HBsAg affect its immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Virus-like particles-universal molecular toolboxes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.009

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.08.009

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39845890&oldid=2091408137"